Inspire Medical Systems, Inc.
Inspire Medical Systems Announces FDA Approval for Inspire V Therapy System
Summary
On August 2, 2024, Inspire Medical Systems, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its Inspire V therapy system, which includes the next generation neurostimulator and associated Bluetooth patient remote and physician programmer. The company plans a soft launch in late 2024 and a full launch in 2025. The FDA approval is a significant milestone for Inspire Medical Systems and for the treatment of obstructive sleep apnea.
Profitelligence Alerts
Get alerts for INSP
Be first to know when Inspire Medical Systems, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc. is a pioneering company focused on developing and commercializing innovative medical technology designed to treat obstructive sleep apnea (OSA). The company's flagship product, the Inspire therapy, is an implantable neurostimulation device that provides a unique and effective solution for patients who are unable to utilize traditional continuous positive airway pressure (CPAP) devices. Inspire Medical Systems significantly impacts the healthcare sector by offering a less invasive, patient-friendly alternative to surgical treatments for OSA, improving quality of life for those affected by sleep disorders. Headquartered in Minnesota, Inspire Medical Systems continues to expand its presence within the medical device market, collaborating closely with hospitals and medical professionals to enhance sleep health management globally. This company's contributions underscore a growing focus on personalized and technologically advanced approaches to medical challenges, marking its importance in the evolving landscape of healthcare solutions.
Official SEC Documents
Advertisement